PTK2 and renal cell carcinoma: Their results showed PTK2 phosphorylation to be ubiquitous across all RCC samples analyzed, with a tyrosine kinase inhibitor screen consisting of 63 compounds showing those targeting PTK2 to have the most robust response in vitro.